Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

“We are very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time,” said Allan Wehnert, CEO & Founder of Orocidin. “This ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

The life sciences industry has recently been rocked by dramatic changes in how healthcare is provided, how drugs are developed and researched, the technologies available that enable companies to ...

Even for an industry that depends on relentless innovation to thrive, life sciences have seen remarkable advancements in recent decades. From the Human Genome Project paving the way for precision ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...